S&P 500   3,335.47 (-0.48%)
DOW   27,452.66 (-0.48%)
QQQ   276.21 (-0.36%)
AAPL   114.01 (-0.83%)
MSFT   207.41 (-0.97%)
FB   262.52 (+2.22%)
GOOGL   1,465.84 (+0.49%)
AMZN   3,145.92 (-0.89%)
TSLA   417.86 (-0.79%)
NVDA   529.07 (+1.47%)
BABA   276.94 (+0.34%)
CGC   14.50 (+2.04%)
GE   6.12 (-1.29%)
MU   50.88 (+2.33%)
AMD   81.84 (+2.97%)
T   28.30 (-0.28%)
F   6.59 (-1.49%)
ACB   4.69 (-1.88%)
GILD   62.08 (-1.23%)
NFLX   493.92 (+0.67%)
DIS   125.13 (-0.68%)
BA   164.10 (-1.19%)
BAC   23.81 (-1.16%)
S&P 500   3,335.47 (-0.48%)
DOW   27,452.66 (-0.48%)
QQQ   276.21 (-0.36%)
AAPL   114.01 (-0.83%)
MSFT   207.41 (-0.97%)
FB   262.52 (+2.22%)
GOOGL   1,465.84 (+0.49%)
AMZN   3,145.92 (-0.89%)
TSLA   417.86 (-0.79%)
NVDA   529.07 (+1.47%)
BABA   276.94 (+0.34%)
CGC   14.50 (+2.04%)
GE   6.12 (-1.29%)
MU   50.88 (+2.33%)
AMD   81.84 (+2.97%)
T   28.30 (-0.28%)
F   6.59 (-1.49%)
ACB   4.69 (-1.88%)
GILD   62.08 (-1.23%)
NFLX   493.92 (+0.67%)
DIS   125.13 (-0.68%)
BA   164.10 (-1.19%)
BAC   23.81 (-1.16%)
S&P 500   3,335.47 (-0.48%)
DOW   27,452.66 (-0.48%)
QQQ   276.21 (-0.36%)
AAPL   114.01 (-0.83%)
MSFT   207.41 (-0.97%)
FB   262.52 (+2.22%)
GOOGL   1,465.84 (+0.49%)
AMZN   3,145.92 (-0.89%)
TSLA   417.86 (-0.79%)
NVDA   529.07 (+1.47%)
BABA   276.94 (+0.34%)
CGC   14.50 (+2.04%)
GE   6.12 (-1.29%)
MU   50.88 (+2.33%)
AMD   81.84 (+2.97%)
T   28.30 (-0.28%)
F   6.59 (-1.49%)
ACB   4.69 (-1.88%)
GILD   62.08 (-1.23%)
NFLX   493.92 (+0.67%)
DIS   125.13 (-0.68%)
BA   164.10 (-1.19%)
BAC   23.81 (-1.16%)
S&P 500   3,335.47 (-0.48%)
DOW   27,452.66 (-0.48%)
QQQ   276.21 (-0.36%)
AAPL   114.01 (-0.83%)
MSFT   207.41 (-0.97%)
FB   262.52 (+2.22%)
GOOGL   1,465.84 (+0.49%)
AMZN   3,145.92 (-0.89%)
TSLA   417.86 (-0.79%)
NVDA   529.07 (+1.47%)
BABA   276.94 (+0.34%)
CGC   14.50 (+2.04%)
GE   6.12 (-1.29%)
MU   50.88 (+2.33%)
AMD   81.84 (+2.97%)
T   28.30 (-0.28%)
F   6.59 (-1.49%)
ACB   4.69 (-1.88%)
GILD   62.08 (-1.23%)
NFLX   493.92 (+0.67%)
DIS   125.13 (-0.68%)
BA   164.10 (-1.19%)
BAC   23.81 (-1.16%)
Log in
NYSE:AZN

AstraZeneca Stock Forecast, Price & News

$55.05
+0.30 (+0.55 %)
(As of 09/29/2020 03:58 PM ET)
Add
Compare
Today's Range
$54.54
Now: $55.05▼
$55.20
50-Day Range
$53.07
MA: $55.32▼
$57.01
52-Week Range
$36.15
Now: $55.05▼
$64.94
Volume267,668 shs
Average Volume5.24 million shs
Market Capitalization$144.47 billion
P/E Ratio66.33
Dividend Yield1.59%
Beta0.5
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
Read More
AstraZeneca logo

Beat the Market (BTM) Rank™

Analyst Opinion: 2.2Community Rank: 1.9Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.58 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:AZN
Previous Symbol
CUSIPN/A
CIK901832
Webwww.astrazeneca.com
Phone44-20-3749-5000

Debt

Debt-to-Equity Ratio1.14
Current Ratio0.82
Quick Ratio0.63

Price-To-Earnings

Trailing P/E Ratio66.33
Forward P/E Ratio27.12
P/E Growth1.63

Sales & Book Value

Annual Sales$24.38 billion
Price / Sales5.92
Cash Flow$3.14 per share
Price / Cash Flow17.52
Book Value$5.56 per share
Price / Book9.90

Profitability

EPS (Most Recent Fiscal Year)$1.75
Net Income$1.34 billion
Net Margins8.36%
Return on Equity37.72%
Return on Assets8.60%

Miscellaneous

Employees70,600
Outstanding Shares2,624,374,000
Market Cap$144.47 billion
Next Earnings Date10/22/2020 (Estimated)
OptionableOptionable
$55.05
+0.30 (+0.55 %)
(As of 09/29/2020 03:58 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AZN News and Ratings via Email

Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











AstraZeneca (NYSE:AZN) Frequently Asked Questions

How has AstraZeneca's stock been impacted by Coronavirus?

AstraZeneca's stock was trading at $44.58 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AZN shares have increased by 23.5% and is now trading at $55.05.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of AstraZeneca?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 2 sell ratings, 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for AstraZeneca.

When is AstraZeneca's next earnings date?

AstraZeneca is scheduled to release its next quarterly earnings announcement on Thursday, October 22nd 2020.
View our earnings forecast for AstraZeneca.

How were AstraZeneca's earnings last quarter?

AstraZeneca plc (NYSE:AZN) released its earnings results on Thursday, July, 30th. The company reported $0.48 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.44 by $0.04. The business had revenue of $6.28 billion for the quarter, compared to analysts' expectations of $6.27 billion. AstraZeneca had a net margin of 8.36% and a return on equity of 37.72%. The company's revenue was up 9.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.73 earnings per share.
View AstraZeneca's earnings history.

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca announced a semi-annual dividend on Friday, July 31st. Shareholders of record on Friday, August 14th will be given a dividend of $0.45 per share on Monday, September 14th. This represents a dividend yield of 2.5%. The ex-dividend date of this dividend is Thursday, August 13th.
View AstraZeneca's dividend history.

When did AstraZeneca's stock split? How did AstraZeneca's stock split work?

Shares of AstraZeneca split on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly issued shares were payable to shareholders after the market closes on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

What price target have analysts set for AZN?

11 Wall Street analysts have issued 1-year target prices for AstraZeneca's shares. Their forecasts range from $60.00 to $65.00. On average, they expect AstraZeneca's share price to reach $61.67 in the next twelve months. This suggests a possible upside of 12.0% from the stock's current price.
View analysts' price targets for AstraZeneca.

Has AstraZeneca been receiving favorable news coverage?

News headlines about AZN stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AstraZeneca earned a media sentiment score of -1.6 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term.
View the latest news about AstraZeneca.

Are investors shorting AstraZeneca?

AstraZeneca saw a decline in short interest in August. As of August 31st, there was short interest totaling 4,130,000 shares, a decline of 37.2% from the August 15th total of 6,580,000 shares. Based on an average daily trading volume, of 6,690,000 shares, the days-to-cover ratio is presently 0.6 days.
View AstraZeneca's Short Interest.

Who are some of AstraZeneca's key competitors?

Some companies that are related to AstraZeneca include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Sanofi (SNY), Commonwealth Bank of Australia (CSLLY), GlaxoSmithKline (GSK), Celgene (CELG) and Zoetis (ZTS).
View all competitors.

What other stocks do shareholders of AstraZeneca own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include Pfizer (PFE), Gilead Sciences (GILD), Johnson & Johnson (JNJ), NVIDIA (NVDA), Moderna (MRNA), Tesla (TSLA), AbbVie (ABBV), AT&T (T), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

Who are AstraZeneca's key executives?

AstraZeneca's management team includes the following people:
  • Mr. Pascal Soriot, CEO & Exec. Director (Age 60)
  • Mr. Marc Dunoyer, CFO & Exec. Director (Age 67)
  • Ms. Pam P. Cheng, Exec. Vice-Pres of Operations & Information Technology (Age 48)
  • Thomas Kudsk Larsen, Head of Investor Relations
  • Mr. Jefrey Pott, Gen. Counsel

What is AstraZeneca's stock symbol?

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

How do I buy shares of AstraZeneca?

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AstraZeneca's stock price today?

One share of AZN stock can currently be purchased for approximately $55.05.

How big of a company is AstraZeneca?

AstraZeneca has a market capitalization of $144.47 billion and generates $24.38 billion in revenue each year. The company earns $1.34 billion in net income (profit) each year or $1.75 on an earnings per share basis. AstraZeneca employs 70,600 workers across the globe.

What is AstraZeneca's official website?

The official website for AstraZeneca is www.astrazeneca.com.

How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company can be reached via phone at 44-20-3749-5000 or via email at [email protected]

This page was last updated on 9/29/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.